Despite the success achieved with ICIs for the treatment of other solid tumors, the results in the treatment of GC are uncertain, although the benefit appears to be more pronounced in patients with PD-L1+ expression, MSI-H or dMMR tumors [132]. The gene discussed is CD274; the disease is gastric cancer.